These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12241648)

  • 21. [Evaluation of the effects on the composition of alveolar surfactant of 2 chemotherapeutic protocols for carcinoma of the lung: peptichemio and MACC].
    Balbi B; Benatti U; Morelli A; Sacco O; Vassallo F; Rossi GA; Ravazzoni C
    Ann Ital Med Int; 1987; 2(1):22-30. PubMed ID: 3275275
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pegylated liposomal doxorubicin in ovarian cancer treatment].
    Nowak-Markwitz E
    Ginekol Pol; 2009 Aug; 80(8):615-9. PubMed ID: 19824461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of patients with ovarian carcinoma: experimental and clinical studies].
    Kikuchi Y; Kita T; Iwano I; Miyauchi M; Oomori K; Kizawa I; Kato K
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):933-5. PubMed ID: 3418201
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical experience in the treatment of ovarian carcinoma and the role of the nurse during the hemotherapy].
    Zaprjanova P; Kostova I; Stancheva T
    Akush Ginekol (Sofiia); 2009; 48 Suppl 2():33-6. PubMed ID: 20380097
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
    Pérez-López ME; Curiel T; Gómez JG; Jorge M
    Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical results of carboplatin in the treatment of malignant tumors. Clinical Cooperative Group of Carboplatin].
    Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):321-4. PubMed ID: 2177394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of ovarian cancer].
    Kato T; Nishimura H
    Gan No Rinsho; 1989 Jan; Spec No():392-8. PubMed ID: 2464708
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of carboplatin based combination chemotherapy on ovarian cancer.
    Feng Y; Zhang X; Sun H
    Chin Med J (Engl); 1996 May; 109(5):349-52. PubMed ID: 9208489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical aspects of ovarian tumors of low malignant potential.
    Dgani R; Blickstein I; Shoham Z; Czernobilsky B; Ben-Hur H; Shani A; Katz Z; Borenstein R
    Eur J Obstet Gynecol Reprod Biol; 1990; 35(2-3):251-8. PubMed ID: 2159428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.
    Larbi E; Madhuri K; Essapen S; Butler-Manuel S; Tailor A; Michael A
    Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):75. PubMed ID: 23146339
    [No Abstract]   [Full Text] [Related]  

  • 32. Dose intensity in advanced ovarian cancer: have we answered the question?
    Fennelly D
    Clin Cancer Res; 1995 Jun; 1(6):575-82. PubMed ID: 9816018
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.
    Rakowski JA; Ahmad S; Holloway RW
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):31-40. PubMed ID: 22149430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemotherapeutic treatment of advanced ovarian carcinoma. Preliminary results of the Piedmont-Liguria Cooperative Group].
    Conte PF; Rosso R; Bruzzone M; Sertoli MR; Rubagotti A; Santi L; Carnino F; Cottini M; Mossetti C; Gatti M
    Minerva Ginecol; 1984 Apr; 36(4):213-6. PubMed ID: 6547773
    [No Abstract]   [Full Text] [Related]  

  • 35. New developments with carboplatin in the treatment of ovarian cancer.
    Ozols RF
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):85-9. PubMed ID: 1411631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.
    ten Bokkel Huinink WW; Dalesio O; Rodenhuis S; Dubbelman R; Hilton A; Franklin H; Koier I; van Tinteren H; van der Burg ME; van Oosterom AT
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):99-101. PubMed ID: 1411634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy induced refractory anaemia with ring sideroblasts in carcinoma breast.
    Dhot PS; Sharma MC; Kumar L; Saxena R
    J Assoc Physicians India; 1994 Feb; 42(2):153-4. PubMed ID: 7860480
    [No Abstract]   [Full Text] [Related]  

  • 39. Regimens with intraperitoneal cisplatin plus intravenuous cyclophosphamide and intraperitoneal carboplatin plus intravenuous cyclophosphamide are equally effective in second line intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Sznurkowski J; Emerich J
    Adv Med Sci; 2012 Jun; 57(1):46-50. PubMed ID: 22430042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose intensity regimens with epirubicin in ovarian cancer.
    Vermorken JB
    Pathol Biol (Paris); 1992 Nov; 39(9):833. PubMed ID: 1538894
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.